Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%
Details : Lidocaine hydrochloride is a local anesthetic used in a wide variety of superficial and invasive procedures, it works by blocking sodium channels and thus decreasing the rate of contractions of the heart.
Product Name : Lidocaine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : Lidocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP-100
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
Details : AMP-100 is a patented, innovative ocular surface anesthetic drug candidate, with safety and efficacy supported by a recently completed Phase 3 study that successfully compared the efficacy and tolerability of AMP-100 to current standards of care.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : AMP-100
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chloroprocaine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2020
Lead Product(s) : Chloroprocaine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chloroprocaine
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2019
Lead Product(s) : Chloroprocaine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2018
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Chloroprocaine 3% - Epidural Anesthesia in Unplanned Caesarean Section
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2016
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2016
Lead Product(s) : Paracetamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable